Investor Alert: Corcept Therapeutics Inc. Facing Class Action Lawsuit, Robbins LLP Reports

A class action lawsuit has been filed on behalf of investors who bought or acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025. Corcept is a pharmaceutical company specializing in medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders by influencing the hormone cortisol.

The lawsuit alleges that Corcept misrepresented the viability of its new product candidate, relacorilant, during this period. This drug was being developed to treat hypercortisolism, also known as Cushing’s syndrome, among other indications. Throughout the class period, the defendants claimed that the key clinical trials supporting relacorilant were robust evidence for the New Drug Application submitted to the FDA. They reassured investors about the submission and anticipated approval without any obstacles. Towards the end of the period, they repeatedly assured investors that relacorilant was on track for approval.

However, it is alleged that the FDA raised concerns about the clinical evidence supporting the NDA, posing a material risk to approval. On December 31, 2025, Corcept disclosed that the FDA had issued a Complete Response Letter regarding the NDA for relacorilant. The FDA could not establish a favorable benefit-risk assessment without additional evidence of effectiveness from Corcept. Consequently, the stock price plummeted from $70.20 on December 30, 2025, to $34.80 on December 31, 2025, a drop of 50.4%.

Investors who acquired Corcept stock during the mentioned period may be eligible to join the class action lawsuit against the company. Lead plaintiffs, representing other class members in the legal proceedings, can be nominated. Participation in the lawsuit is not mandatory to be eligible for potential recoveries. In cases where shareholders do not participate, they will still be considered absent class members.

Robbins LLP, known for its work in shareholder rights litigation since 2002, is representing the investors. The firm operates on a contingency fee basis, meaning shareholders do not incur fees or expenses. Those interested in updates on the lawsuit settlement or alerts concerning corporate executive misconduct can register for Stock Watch for free.

This article serves as attorney advertising and does not guarantee the same results for every case. For more information about the class action or general inquiries, contact Aaron Dumas, Jr. at Robbins LLP in San Diego.